GlassScriptPhysician profile
Ambika A Softa
NPI 1770580912
$6,019.10
in general payments reported to CMS, 2019-2025
36 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $227 · 2021: $196 · 2022: $953 · 2023: $1,269 · 2024: $1,087 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,318.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $747.58 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $703.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $488.11 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $451.55 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $379.22 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $205.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $165.64 | 2019-2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $146.30 | 2023-2025 | |
| Abbvie INC. | $143.21 | 2019-2022 | |
| Biosense Webster, INC. | $143.01 | 2024-2025 | Qdot Micro, Qdot Micro Catheter |
| Dexcom, INC. | $141.34 | 2022-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $123.95 | 2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $101.90 | 2024-2025 | Voquezna |
| Abbott Laboratories | $80.57 | 2022-2025 | Freestyle Libre 3 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambika Softa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.